Quality assurance of allergen-specific immunotherapy during a national outbreak of anaphylaxis: Results of a continuous sentinel event surveillance system

Journal of Investigational Allergology and Clinical Immunology

Volumn 19, Issue 4, 2009, Pages 253-259

  Madsen, Flemming ^a   Frolund L ^b   Christensen, M ^c   Frost, A ^d   Petersen, U Søes ^e  

^a Allergy and Lungclinic Helsingør ^*  (Denmark)

^b Allergy and Lungclinic Hellerup   (Denmark)

^c Lung and Allergy Clinic Aabenraa   (Denmark)

^d Specialist Clinic Hellerup   (Denmark)

^e ROSKILDE HOSPITAL   (Denmark)

Author keywords

Allergen; Allergen immunotherapy; Immunotherapies; Risk; Risk management; Safety; Sentinel surveillance

Indexed keywords

ALLERGEN;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; BEE; BIRCH; CAT; CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DISEASE SURVEILLANCE; DOG; DRUG SAFETY; GRASS; HEALTH CARE MANAGEMENT; HEALTH SURVEY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MITE; MULTICENTER STUDY; PATIENT SAFETY; PHYSICIAN; PROSPECTIVE STUDY; QUALITY CONTROL; RISK FACTOR; RISK MANAGEMENT; WASP; DESENSITIZATION; EPIDEMIC; HEALTH CARE PLANNING; HEALTH CARE QUALITY; INFORMATION SERVICE; STANDARD;

ANAPHYLAXIS; DENMARK; DESENSITIZATION, IMMUNOLOGIC; DISEASE OUTBREAKS; HEALTH PLANNING GUIDELINES; HUMANS; INFORMATION SERVICES; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; RISK MANAGEMENT;

EID: 68849106415     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969-974
2. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;24;(1):CD001936. Review. (Pubitemid 351820381)
3. Álvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61 Suppl 82:1-20.
4. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113:1129-1136
5. Cox L, Li JT, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter second update. J Allergy Clin Immunol. 2007;120:S25-S85. (Pubitemid 47313519)
6. Frew AJ. Immunotherapy: how safe is safe? Clin Exp Allergy. 2006;36:251-253
7. Danish Pharmacy Agency. Consumption and Statistics. Accessed May 30, 2009. http://www.dkma.dk/1024/visUKLSArtikel. asp?artikelID=11739.
8. Keogh B, Spiegelhalter D, Bailey A, Roxburgh J, Magee P, Hilton C. The legacy of Bristol: public disclosure of individual surgeons' results. BMJ. 2004;329:450-454 (Pubitemid 39141484)
9. Sismanidis C, Bland M, Poloniecki J. Properties of the cumulative risk-adjusted mortality (CRAM) chart, including the number of deaths before a doubling of the death rate is detected. Med Decis Making. 2003;23:242-251 (Pubitemid 36618065)
10. The Joint Commission. Looking at the ORYX Data. [Cited 2008 Jun 26]. Available from: http://www.jointcommission.org/AccreditationPrograms/ BehavioralHealthCare/ORYX/looking-at-oryx-data.htm
11. The Joint Commission. Reporting of Medical/Health Care Errors. [Cited 2009] May 11]. Available from: http://www. jointcommission.org/SentinelEvents/ errors.htm
12. Malling HJ, Weeke B. Immunotherapy. Position paper. Allergy. 1993;48 Suppl.14:9-35.
13. Vincent C, Taylor-Adams S, Chapman EJ, Hewett D, Prior S, Strange P, Tizzard A. How to investigate and analyse clinical incidents: Clinical Risk Unit and Association of Litigation and Risk Management protocol. BMJ. 2000;320:777. (Pubitemid 30179432)
14. Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995;311:619-620
15. Danish Pharmacy Agency. [Summary of product characteristics]. ALK 225 Phleum pratense. [Cited 2008 Jun 26]. Available from: http://www.produktresume. dk/docushare/dsweb/Get/ Document-19295/ALK+225+Phleum+pratense%2C+injekti onsv%C3%A6ske%2C+suspension+til+subkutan+anvendel se+%28Alutard+SQ%29.doc
16. Kuehn BM. FDA Turns to Electronic "Sentinel" to Flag Prescription Drug Safety Problems. JAMA. 2008;300:156-157
17. Kondro W. Adverse reaction database has minimal information. CMAJ. 2005;173:137.
18. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Sideeffects of allergen-specific immunotherapy. A prospective multi-centre study. Clin Exp Allergy. 2006;36:254-260
19. Lin MS, Tanner E, Lynn J, Friday GAJ. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy. 1993;71:557-562 (Pubitemid 24005750)
20. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;34:527-531 (Pubitemid 38534882)
21. Nettis E, Giordano D, Ferrannini A, Tursi A. Systemic reactions to allergen immunotherapy: a review of the literature. Immunopharmacol Immunotoxicol. 2003;25:1-11. (Pubitemid 36359198)
22. Ragusa FV, Passalacqua G, Gambardella R, Campanari S, Barbieri MM, Scordamaglia A, Canonica GW. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol. 1997;7:151-154 (Pubitemid 27344627)
23. Tinkelman D, Cole W, Tunno J. Immunotherapy: A one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol. 1995;95:8-14.
24. Mellerup MT, Hahn GW, Poulsen LK, Malling HJ. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000;30:1423-1429
25. Dursun AB, Sin BA, Oner F, Misirligil Z. The safety of allergen immunotherapy (IT) in Turkey. J Investig Allergol Clin Immunol. 2006;16:123-128
26. Mosbech H, Muller U, behalf of the Study Group*. Sideeffects of insect venom immunotherapy:results from an EAACI multicenter study. Allergy. 2000;55:1005-1010
27. Borchers AT, Keen CL, Gershwin ME. Fatalities following allergen immunotherapy. Clin Rev Allergy Immunol. 2004;27:147-158
28. Li JT, Lockey RF, Bernstein IL, Portnoy JM, Nicklas RA. Allergen Immunotherapy: A Practice Parameter. Ann Allergy Asthma Immunol. 2003;90 s1:1-40.
29. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79:660-677
30. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001;87:47-55.
31. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol. 2004;113:1117-1121
32. Madsen F, Christensen M, Frolund L, Soes-Petersen U, Frost A. Sentinel surveillance of risk associated with specifi c allergy vaccination (SAV). Quality assurance of a clinical procedure with few but serious side effects. Eur Respir J 26[Suppl. 49], 526s. 2005.